These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 637906)

  • 1. Thymidine rescue of high-dose methotrexate in humans.
    Howell SB; Ensminger WD; Krishan A; Frei E
    Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of methotrexate toxicity by thymidine infusions in humans.
    Ensminger WD; Frei E
    Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
    Howell SB; Krishan A; Frei E
    Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
    Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
    Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative biochemical aspects of low and high doses of methotrexate in mice.
    Zaharko DS; Fung WP; Yang KH
    Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
    Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
    Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine requirements for the rescue of patients treated with high-dose methotrexate.
    Howell SB; Herbst K; Boss GR; Frei E
    Cancer Res; 1980 Jun; 40(6):1824-9. PubMed ID: 7371013
    [No Abstract]   [Full Text] [Related]  

  • 10. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
    Pinedo HM; Zaharko DS; Bull J; Chabner BA
    Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.
    Glode LM; Pitman SW; Ensminger WD; Rosowsky A; Papathanasopoulos N; Frei E
    Cancer Res; 1979 Sep; 39(9):3707-14. PubMed ID: 383286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients.
    Blumenreich MS; Woodcock TM; Andreeff M; Hiddemann W; Chou TC; Vale K; O'Hehir M; Clarkson BD; Young CW
    Cancer Res; 1984 May; 44(5):2203-7. PubMed ID: 6713407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.
    Stoller RG; Kaplan HG; Cummings FJ; Calabresi P
    Cancer Res; 1979 Mar; 39(3):908-12. PubMed ID: 311683
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion.
    Chiuten DF; Wiernik PH; Zaharko DS; Edwards L
    Cancer Res; 1980 Mar; 40(3):818-22. PubMed ID: 7471098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate with thymidine protection or rescue in advanced head and neck cancer: a phase II study.
    Schornagel JH; Leyva A; Pinedo HM
    Cancer Treat Rep; 1984 Mar; 68(3):543-5. PubMed ID: 6704983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.